Kiren Sahni
Rheumatology · West Long Branch, NJNPI 1073932554
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $511,242 of the $569,281 with a category attached, or 89.8%. 37 manufacturers reported payments, led by Amgen at 32.2% of the total. Among rheumatology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,072 payments — averaging $274.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$183K
- AbbVie$176K
- Johnson & Johnson$62K
- GSK$49K
- Pfizer$36K
- AstraZeneca$34K
- plus $28K from 31 others
Across 23 payments — averaging $6987.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$97K
- Aurinia Pharma U.S., Inc.$26K
- Novartis$22K
- Sanofi US Services Inc.$10K
- E.r. Squibb & Sons, L.L.C.$3K
- Pfizer$2K
What the payments were for
- Consulting fees$13,0662%
- Speaking & faculty fees$511,24290%
- Travel & lodging$16,5623%
- Food & beverage$27,7505%
- Education$6620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 481 | $183,499 |
| AbbVie | 402 | $176,449 |
| Johnson & Johnson(2 entities) | 269 | $62,131 |
| GSK | 104 | $49,099 |
| Pfizer | 155 | $36,372 |
| AstraZeneca(2 entities) | 156 | $33,858 |
| Janssen Scientific Affairs, LLC | 8 | $9,100 |
| E.r. Squibb & Sons, L.L.C. | 121 | $5,726 |
| UCB, Inc. | 91 | $4,995 |
| Aurinia Pharma U.S., Inc. | 63 | $4,285 |
| Novartis | 63 | $1,258 |
| ANI Pharmaceuticals, Inc. | 34 | $464 |
| Lilly USA, LLC | 25 | $343 |
| Genentech USA, Inc. | 18 | $305 |
| Mallinckrodt Hospital Products Inc. | 18 | $263 |
| Sanofi | 10 | $195 |
| Cvrx, Inc. | 5 | $128 |
| Radius Health, Inc. | 7 | $117 |
| Sobi, Inc | 7 | $114 |
| Fresenius Kabi USA, LLC | 3 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $58 |
| Boehringer Ingelheim | 4 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Bioventus LLC | 2 | $38 |
| Invivyd Inc | 2 | $38 |
| Organon | 2 | $34 |
| Almatica Pharma LLC | 2 | $33 |
| Abbott | 2 | $32 |
| Orthogenrx Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $31 |
| Pacira Therapeutics, Inc. | 1 | $26 |
| Si-bone, Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Avanos Medical | 1 | $12 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$569,281 in reported general payments places this provider in the 95th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 29 | $200,576 |
| OtezlaApremilast | 12 | $57,195 |
| MethotrexateMethotrexate Sodium | 280 | $10,375 |
| Leflunomide | 105 | $9,156 |
| Hydroxychloroquine Sulfate | 120 | $6,230 |
| Pregabalin | 35 | $2,576 |
| Lidocaine | 12 | $2,422 |
| Celecoxib | 62 | $2,334 |
| Colchicine | 19 | $2,155 |
| Gabapentin | 74 | $1,603 |
| Prednisone | 237 | $1,121 |
| Sulfasalazine | 26 | $632 |
| Meloxicam | 101 | $581 |
| Risedronate Sodium | 11 | $517 |
| Diclofenac Sodium | 18 | $490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $176,449 | $200,57629 claims |
| AmgenOtezla | $183,499 | $57,19512 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $16 | $2,15519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in West Long Branch
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
- Nickolas TyrisSewell$201K
- Anan HaijaGalloway$196K
- Evan LeibowitzMidland Park$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.